2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-176480
    CYP11B2-IN-3 3072732-90-9
    CYP11B2-IN-3 (compound 32) is an orally active and selective CYP11B2 inhibitor with IC50 values of 12.92 nM and 2341 nM for CYP11B2 and CYP11B1, respectively. CYP11B2-IN-3 can be used for study of hypertension.
    CYP11B2-IN-3
  • HY-176493
    GLP-1R agonist 33 2428641-93-2
    GLP-1R agonist 33 (Compound 224) is a GLP-1 receptor agonist. GLP-1R agonist 33 has the potential to study diabetes, obesity and non-alcoholic fatty liver disease (NAFLD).
    GLP-1R agonist 33
  • HY-176714
    VUF26034
    VUF26034 (Compound 12b) is a photoresponsive ligand for the human β2-adrenergic receptor (β2-AR.
    VUF26034
  • HY-176716
    ALDH2 activator 1 2988020-77-3
    ALDH2 activator 1 (Compound Z17) is an allosteric aldehyde dehydrogenase 2 (ALDH2) agonist. ALDH2 activator 1 enhances cardiac function and reduces myocardial necrosis in a mouse model of myocardial ischemia-reperfusion. ALDH2 activator 1 is promising for research of cardiovascular diseases such as myocardial infarction (MI).
    ALDH2 activator 1
  • HY-18200A
    Atopaxar hydrochloride 474544-83-7 98%
    Atopaxar hydrochloride (E5555 hydrochloride) is the hydrochloride salt form of Atopaxar (HY-18200). Atopaxar hydrochloride is an orally active, selective and reversible antagonist for thrombin receptor protease-activated receptor-1 (PAR-1). Atopaxar hydrochloride is the inhibitor for Janus kinase 1 (JAK1) and JAK2, which inhibits the JAK-STAT with EC50 of 5.90 μM in A549. Atopaxar hydrochloride inhibits the cell viability of A549 (IC50=7.02 μM), arrests the cell cycle at G1 phase and induces apoptosis. Atopaxar hydrochloride exhibits antiplatelet and antitumor activities. Atopaxar hydrochloride can be used for the research of atherothrombotic disease.
    Atopaxar hydrochloride
  • HY-18200B
    Atopaxar hydrobromide 474550-69-1 98%
    Atopaxar (E5555) hydrobromide is a potent, orally active, selective and reversible thrombin receptor protease-activated receptor-1 (PAR-1) antagonist. Atopaxar hydrobromide, an antiplatelet agent, interferes with platelet signaling. Atopaxar hydrobromide can be used for the research of atherothrombotic disease.
    Atopaxar hydrobromide
  • HY-18204R
    Valsartan (Standard) 137862-53-4
    Valsartan (Standard) is the analytical standard of Valsartan. This product is intended for research and analytical applications. Valsartan (CGP 48933) is an angiotensin II receptor antagonist and has the potential for high blood pressure and heart failure research.
    Valsartan (Standard)
  • HY-18252R
    Avanafil (Standard) 330784-47-9
    Avanafil (Standard) is the analytical standard of Avanafil. This product is intended for research and analytical applications. Avanafil (TA-1790) is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC50 values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil can be used for the research of erectile dysfunction and osteoporosis.
    Avanafil (Standard)
  • HY-18252S
    Avanafil-13C,d3 2738376-89-9 98%
    Avanafil-13C,d3 is the 13C- and deuterium labeled Avanafil.
    Avanafil-13C,d3
  • HY-18600B
    (E)-Azimilide 1294552-65-0 98%
    (E)-Azimilide is an isomer of Azimilide (HY-18600), a class of antiarrhythmic compounds that inhibit I(Ks) and I(Kr) activity.
    (E)-Azimilide
  • HY-18660A
    Ciraparantag TFA 1438492-27-3 98%
    Ciraparantag (PER977) TFA is a thrombin and factor Xa inhibitor. Ciraparantag TFA is a broad-spectrum reversal agent for anticoagulants, including low-molecular-weight heparin, unfractionated heparin, and certain direct oral anticoagulants. It is reported to antagonize the effects of all coagulants except VKAs and agratroban.
    Ciraparantag TFA
  • HY-18660S
    Ciraparantag-d8 (tetra(hydrochloride) diacetate) 98%
    Ciraparantag-d8 (PER977-d8) tetrahydrochloride diacetate is the deuterium labeled Ciraparantag (HY-18660). Ciraparantag is a thrombin and factor Xa inhibitor. Ciraparantag is a broad-spectrum reversal agent for anticoagulants, including low-molecular-weight heparin, unfractionated heparin, and certain direct oral anticoagulants. It is reported to antagonize the effects of all coagulants except VKAs and agratroban.
    Ciraparantag-d8 (tetra(hydrochloride) diacetate)
  • HY-18732B
    L-NMMA citrate 209913-88-2 98%
    L-NMMA citrate competitively antagonizes L-arginine, and thus inhibits production of nitric oxide (NO). L-NMMA is utilized as NO synthase antagonist in experimental settings.
    L-NMMA citrate
  • HY-18763A
    Indobufen sodium 94135-04-3 98%
    Indobufen sodium is a platelet aggregation inhibitor. Indobufen sodium is a reversible platelet cyclooxygenase (Cox) activity inhibitor. Indobufen sodium suppresses thromboxane A2 (TxA2) synthesis. Indobufen sodium down-regulates tissue factor (TF) in monocytes.
    Indobufen sodium
  • HY-18763S
    Indobufen-d5 98%
    Indobufen-d5 is deuterium labeled Indobufen. Indobufen is a platelet aggregation inhibitor. Indobufen is a reversible platelet cyclooxygenase (Cox) activity inhibitor. Indobufen suppresses thromboxane A2 (TxA2) synthesis. Indobufen down-regulates tissue factor (TF) in monocytes.
    Indobufen-d5
  • HY-19003A
    Isomazole hydrochloride 87359-33-9 98%
    Isomazole (323MHb) hydrochloride is a cardiotonic agent. Isomazole hydrochloridei increases the calcium sensitivity in atrial fibers and has a direct effect on contractile proteins.
    Isomazole hydrochloride
  • HY-19155A
    ICI-D 8731 135015-84-8 98%
    ICI-D 8731 (compound 5g) is a angiotensin II receptor antagonist with the IC50 of 0.031 μM. ICI-D 8731 shows a rapid and sustained lowering of blood pressure in a renal hypertensive rat model.
    ICI-D 8731
  • HY-19399B
    Iroxanadine sulfate 276690-61-0 98%
    Iroxanadine (BRX 005) sulfate is a vasculoprotector. Iroxanadine is a p38 kinase and HSP protein dual activator. Iroxanadine sulfate has the potential for atherosclerosis and vascular diseases research.
    Iroxanadine sulfate
  • HY-19463A
    F15845 470454-73-0 98%
    F 15845 is a highly effective persistent sodium current blocker. F 15845 also is a cardioprotective agent, has anti-ischemic activity and exerts short- and long-term cardioprotection after myocardial infarction. F 15845 can be used for the research of myocardium functional impairment.
    F15845
  • HY-19679A
    Quinacainol dihydrochloride 83255-74-7 98%
    Quinacainol dihydrochloride (PK 10139 dihydrochloride) is the dihydrochloride salt form of Quinacainol (HY-19679). Quinacainol dihydrochloride is an inhibitor for sodium current with an EC50 of 95 µM. Quinacainol dihydrochloride exhibits antiarrhythmic activity by affecting the electrophysiological properties of the heart.
    Quinacainol dihydrochloride
Cat. No. Product Name / Synonyms Application Reactivity